MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs

Chen, Rijiang; Qiu, Hanmin; Tong, Yan; Liao, Fake; Hu, Xiunian; Qiu, Yong-Rong; Liao, Yuanjun

doi:10.1016/j.bbrc.2019.06.083

Cited by 53 publications

(40 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-19a-3p is dysregulated in a variety of cancers and participates in the mediation of many biological processes, but its role in OP is not yet well known. In their study, Chen R et al highlighted the ability of this miR to promote hBMSC osteogenic differentiation via binding the HDAC4 gene, which was proven to inhibit osteogenic differentiation-related markers expression [42]. In addition, they reported that miR-19a-3p serum levels in OP patients (n = 42) were significantly lower than in healthy subjects (n = 42).…”

Section: Pm Op/ope Vs Pm Ctrsmentioning

confidence: 99%

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Ciuffi

Donati

Marini

et al. 2020

IJMS

View full text Add to dashboard Cite

Osteoporosis is a multifactorial skeletal disease that is associated with both bone mass decline and microstructure damage. The fragility fractures—especially those affecting the femur—that embody the clinical manifestation of this pathology continue to be a great medical and socioeconomic challenge worldwide. The currently available diagnostic tools, such as dual energy X-ray absorptiometry, Fracture Risk Assessment Tool (FRAX) score, and bone turnover markers, show limited specificity and sensitivity; therefore, the identification of alternative approaches is necessary. As a result of their advantageous features, such as non-invasiveness, biofluid stability, and easy detection, circulating cell-free miRs are promising new potential biomarkers for the diagnosis of osteoporosis and low-traumatic fracture risk assessment. However, due to the absence of both standardized pre-analytical, analytical, and post-analytical protocols for their measurement and universally accepted guidelines for diagnostic use, their clinical utility is limited. The aim of this review was to record all the data currently available in the literature concerning the use of circulating microRNAs as both potential biomarkers for osteoporosis diagnosis and fragility fracture risk evaluation, and group them according to the experimental designs, in order to support a more conscious choice of miRs for future research in this field.

show abstract

Section: Pm Op/ope Vs Pm Ctrsmentioning

confidence: 99%

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Ciuffi

Donati

Marini

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Dalle et al 42 found a lower OPG (osteoprotegerin)/RANKL ratio in the supernatants of osteoblastic culture from patients with osteoporosis than that from normal donors, which caused an alteration of osteoblastic differentiation and might contribute to the pathogenesis of osteoporosis. Abnormal miRNA levels are also involved in the occurrence of primary osteoporosis through regulating osteoclast and osteoblast differentiation 43,44 . Therefore, disorders of important factors and signalling pathways regulating MSC differentiation in the microenvironment may cause an imbalance of bone metabolism, eventually leading to osteoporosis.…”

Section: Mscs In the Pathogenesis Of Osteoporosismentioning

confidence: 99%

Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis

et al. 2020

View full text Add to dashboard Cite

Osteoporosis is a systemic metabolic bone disease with characteristics of bone loss and microstructural degeneration. The personal and societal costs of osteoporosis are increasing year by year as the ageing of population, posing challenges to public health care. Homing disorders, impaired capability of osteogenic differentiation, senescence of mesenchymal stem cells (MSCs), an imbalanced microenvironment, and disordered immunoregulation play important roles during the pathogenesis of osteoporosis. The MSC transplantation promises to increase osteoblast differentiation and block osteoclast activation, and to rebalance bone formation and resorption. Preclinical investigations on MSC transplantation in the osteoporosis treatment provide evidences of enhancing osteogenic differentiation, increasing bone mineral density, and halting the deterioration of osteoporosis. Meanwhile, the latest techniques, such as gene modification, targeted modification and co‐transplantation, are promising approaches to enhance the therapeutic effect and efficacy of MSCs. In addition, clinical trials of MSC therapy to treat osteoporosis are underway, which will fill the gap of clinical data. Although MSCs tend to be effective to treat osteoporosis, the urgent issues of safety, transplant efficiency and standardization of the manufacturing process have to be settled. Moreover, a comprehensive evaluation of clinical trials, including safety and efficacy, is still needed as an important basis for clinical translation.

show abstract

“…It was reported that miR-19a-3p expression in osteoporosis patients was decreased and miR-19a-3p overexpression was demonstrated to target HDAC4 and increase the expression of ALP, OCN, and Runx2. This increased expression resulted in stimulated osteogenic differentiation of hMSCs [79]. RICTOR is known to repress the activity of PPARγ, a transcriptional factor involved in adipogenesis, and prevent MSCs adipogenic differentiation.…”

Section: Mirnas Involved In Bmscs Fate Through Epigenetic Routementioning

confidence: 99%

The Role of MicroRNAs in Bone Metabolism and Disease

Gao

Patil

Qian

2020

IJMS

View full text Add to dashboard Cite

Bone metabolism is an intricate process involving various bone cells, signaling pathways, cytokines, hormones, growth factors, etc., and the slightest deviation can result in various bone disorders including osteoporosis, arthropathy, and avascular necrosis of femoral head. Osteoporosis is one of the most prevalent disorders affecting the skeleton, which is characterized by low bone mass and bone mineral density caused by the disruption in the balanced process of bone formation and bone resorption. The current pharmaceutical treatments such as bisphosphonates, selective estrogen receptor modulator, calcitonin, teriparatide, etc., could decrease the risk of fractures but have side-effects that have limited their long term applications. MicroRNAs (miRNAs) are one of many non-coding RNAs. These are single-stranded with a length of 19–25 nucleotides and can influence various cellular processes and play an important role in various diseases. Therefore, in this article, we review the different functions of different miRNA in bone metabolism and osteoporosis to understand their mechanism of action for the development of possible therapeutics.

show abstract

MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs

Cited by 53 publications

References 46 publications

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis

The Role of MicroRNAs in Bone Metabolism and Disease

Contact Info

Product

Resources

About